Indeed, ART-838 was effective with IC50<1μM against every acute leukemia tested, including those harboring poor prognosis mutations such as MLLr and FLT3 internal tandem duplication (FLT3/ITD) [26, 28]. This evidence concerns the gene FLT3 and acute leukemia.